AMG 509

Phase 1

Amgen Inc. (AMGN)

Fast TrackLearn about designations

Phase 1

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

8 competitors in Prostate Cancer

CADLaglatimagene besadenovec

Phase 3

CASIPanzem® NCD

Phase 2

SNYCabazitaxel XRP6258

Phase 2

4503.TCP-461

Phase 2

BTAIBXCL701 plus Pembrolizumab

Phase 2

View Full Landscape

Drug Information

Target Indication

Prostate Cancer

Mechanism of Action

XmAb Bispecific

Clinical Trial

NCT04221542

Last updated: 12/3/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

AMGN

Amgen Inc.

Biological Products, (No Diagnostic Substances)•North America•NASDAQ

Related Pipeline

Denosumab (AMG 162)Phase 3

Postmenopausal Osteoporosis

TarlatamabPhase 3

Small Cell Lung Cancer

Etanercept LiquidPhase 3

Rheumatoid Arthritis

romosozumab HCP administration with PFSPhase 3

Post-Menopausal Osteoporosis

PegaspargasePhase 3

Acute Lymphoblastic Leukemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts